National Coverage Analysis (NCA) Tracking Sheet for Lung Cancer Screening with Low Dose Computed Tomography (CAG-00439N)

National Coverage Analysis (NCA) Tracking Sheet for Lung Cancer Screening with Low Dose Computed Tomography (CAG-00439N)





National Coverage Analyses

Lung Cancer Screening with Low Dose Computed Tomography
     Posted new tracking sheet
http://www.cms.gov/medicare-coverage-database/details/nca-tracking-sheet.aspx?NCAId=274

Due to technical difficulties, we were unable to post the requestor letters with the tracking sheet for Lung Cancer Screening with Low Dose Computed Tomography.

Those documents are attached.



Once the technical issue is resolved, both requester letters will be available with the tracking sheet as per our typical process.

Effective January 1, 2009, CMS is allowed to add coverage of "additional preventive services" if certain statutory requirements are met. Per Section 1861(ddd) of the Social Security Act and implementing regulations at 42 CFR 410.64, CMS may cover "additional preventive services", if it determines through the national coverage determinations (NCD) process that the service is recommended with a grade A (strongly recommends) or grade B (recommends) rating by the United States Preventive Services Task Force (USPSTF) and that it also meets certain other requirements.

CMS has accepted two formal complete requests to initiate a NCA on Lung Cancer Screening with Low Dose Computed Tomography (LDCT), which is recommended with a grade B by the USPSTF for certain persons at high risk for lung cancer based on age and smoking history. The scope of our review is limited to LDCT Screening for lung cancer. We are particularly interested in evidence to inform the identification of patients eligible for screening; the appropriate frequency and duration of screening; facility and provider characteristics that predict benefit or harm; precise criteria for test positivity and the impact of false positive results and followup tests or treatments. We are also soliciting input on the influence of these factors on patient education and informed consent in Medicare beneficiaries including the elderly and younger disabled populations and persons receiving dialysis treatment for end stage renal disease; and on the integration of smoking cessation interventions for current smokers.

On April 30, 2014, we are convening a Medicare Evidence Development and Coverage Advisory Committee (MEDCAC) meeting to review the available evidence on this topic.